GlassScriptPhysician profile
Ho-Kan Cheng
NPI 1881692374
$4,978.57
in general payments reported to CMS, 2019-2025
36 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,457 · 2020: $378 · 2021: $119 · 2022: $98.21 · 2023: $178 · 2024: $701 · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,789 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,789.21 |
| Education | $136.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,105.80 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $726.82 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Genzyme Corporation | $409.24 | 2019-2025 | |
| Olympus Corporation of The Americas | $405.61 | 2019 | |
| Jazz Pharmaceuticals INC. | $291.55 | 2019-2024 | Xywav |
| Regeneron Healthcare Solutions, INC. | $231.52 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.76 | 2019 | |
| Janssen Pharmaceuticals, INC | $123.11 | 2019-2020 | |
| Philips North America LLC | $112.91 | 2019-2024 | (Ak6) Vest Therapy |
| Pfizer INC. | $112.71 | 2019-2025 | |
| Axsome Therapeutics, INC. | $107.49 | 2023-2025 | Sunosi |
| Genentech USA, INC. | $87.04 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $86.58 | 2019-2020 | |
| Grifols USA, LLC | $78.67 | 2019-2025 | Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $74.99 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $71.28 | 2019-2020 | |
| Mylan Specialty L.P. | $69.38 | 2019-2024 | Yupelri |
| Harmony Biosciences LLC | $67.43 | 2020-2025 | |
| Electromed, INC. | $66.77 | 2019 | |
| Circassia INC. | $59.38 | 2019-2020 | |
| United Therapeutics Corporation | $57.77 | 2019-2024 | Tyvaso |
| Avadel Cns Pharmaceuticals, LLC | $57.59 | 2025 | Lumryz |
| Insmed, INC. | $51.93 | 2019-2021 | |
| Viatris Specialty LLC | $35.85 | 2025 | Yupelri |
| Resmed Corp | $35.46 | 2019-2024 | |
| Verona Pharma, INC. | $33.68 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $29.38 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $29.11 | 2019 | |
| Shire North American Group INC | $28.70 | 2019 | |
| Sunovion Pharmaceuticals INC. | $28.11 | 2019 | |
| Vapotherm INC | $24.35 | 2021 | |
| Invivyd INC | $18.89 | 2025 | Pemgarda |
| Azurity Pharmaceuticals, INC. | $15.59 | 2025 | Alvesco |
| Lilly USA, LLC | $15.01 | 2025 | Zepbound |
| Merck Sharp & Dohme LLC | $13.23 | 2019 | |
| Advanced Respiratory, INC | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ho-Kan Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.